medlatest Editorial

Oh dear, medtech industry body is really not sounding happy at the European Parliaments rushed through rule changes. And when they point to the huge cost and delay to market that will result from a bureaucratic behemoth, who are we to argue?

Yep, €17.5Bn. That’s the estimate from (admittedly) the European medtech industry, of what a centralised PMA-style regulatory body would incrementally … continue reading “EuroPMA Will Cost €17.5Bn”

So, five years after first getting a CE mark nod, Medtronic now has enough data to support its peripheral angioplasty balloon as far as module 1 of a PMA submission. Did EU regulatory authorities jump the gun too early or was the US hurdle too high for Invatec ’til Medtronic came along?

Things are undeniably tough, in stateside medtech land. But when the environment changes those that adapt to the brave new world quickly will do best.

Rory McIlroy might (under his breath) be blaming his new golf clubs for his under-performance this year. But when it … continue reading “Who’s Responsible When Devices Don’t Perform?”

Forbes has produced a compellingly straightforward editorial, aimed in part at debunking the myth that the pain of the device … continue reading “Device Tax Gets More Public Airtime”

Medical device sales reps are so numerous as to represent a subspecies all of their own. And they’re hugely expensive … continue reading “Medtech Sales Reps Will Take Some Replacing”

If you work in healthcare you’re probably plagued by the pestering presence of medtech sales reps. But if they weren’t around, would things be better or worse? We argue that for some specialties they’re becoming essential components in healthcare delivery rather than just bringers of doughnuts.

Medical device regulation in Europe is something of a moving target at the moment. Not for much longer though as the pencil pushers are heading us towards a PMA-mimetic system. Just as the FDA is softening its stance. We discuss.

The future of medical provision has a big questionmark hanging over it, simply because somehow we’re going to have to … continue reading “Weekly Blog: Shadowy Medtech Innovation Pricing Doesn’t Help Keep Lid On Costs”

Commentators on healthcare provision point to several factors that they say mean healthcare costs are inexorably rising. People living longer … continue reading “Medtech Europe Boss Challenges Link Between Technology Advances And Cost Increase”

It’s a slight departure, but always good to look for parallels in other industries. Today sees the launch of the … continue reading “New Airbus flies. Can Medtech learn from that Industry?”

The medical device industry brings life-saving and health-giving technology to the world. The funny thing is that from a global … continue reading “This week’s “View From The Med” blog online now”

He might as well have given his answers in Croatian, such are the reported responses provided by new EU commissioner incumbent during a “grilling” by MEPS. I’ve read it three times and I still can derive no meaning from his words.

We’re still clearing up after EuroPCR with a few news items worthy of comment in this week’s editorial.

EuroPCR has been the main focus of medlatest’s editorial this week. We’ve spotted a growing trend for companies to use vehicles like ours to get their news across. Never has that been more evident than this week, which has seen an unprecedented number of winning tales.